Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo

2 May 2013

Abstract excerpt

Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required for tumor initiation and maintenance. To address this question, we expressed oncogenic K-Ras(D12) proteins with "second site" amino acid substitutions that impair PI3 kinase/Akt or Raf/MEK/ERK activation in bone marrow cells and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Chronic Lymphocytic Leukemia Research
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23637129
DOI: 10.1182/blood-2012-05-432252

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivoPMID 23637129Read ↗

Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Somatic activation of oncogenic <i>Kras</i> in hematopoietic cells initiates a rapidly fatal myeloproliferative disorderSemantic proximity Read ↗

Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.Semantic proximity Read ↗

Signaling input from divergent pathways subverts malignant B-cell transformationSemantic proximity Read ↗

Oncogenic Kras Initiates Leukemia in Hematopoietic Stem CellsSemantic proximity Read ↗

KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative DisordersSemantic proximity Read ↗

Oncogenic N-Ras Mitigates Oxidative Stress–Induced Apoptosis of Hematopoietic Stem CellsSemantic proximity Read ↗

KRAS insertion mutations are oncogenic and exhibit distinct functional properties.Semantic proximity Read ↗

K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.Semantic proximity Read ↗

Revisiting RAS family GTPase signaling: effector selectivity and oncogenic bypass.Semantic proximity Read ↗

Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.Semantic proximity Read ↗

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.